Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Clin Immunol ; 101(3): 303-14, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11726223

ABSTRACT

The efficacy of chemotherapy for cancer is often limited by toxicity. Immune approaches to cancer immunotherapy, while promising for specificity and long-term protection, have not typically proven potent enough to generate significant therapeutic responses. We have shown therapeutic benefit using recombinant murine B7.2-Ig (rmB7.2-Ig) in murine tumor models. Efficacy was dependent on immune activity and was not associated with toxicity. Recently, the efficacy of rmB7.2-Ig was demonstrated in leukemia tumor models in combination with chemotherapeutic agents. To further explore the potential of this approach, we evaluated the efficacy in solid tumor models of rmB7.2-Ig given in combination with chemotherapeutics commonly used in clinical practice, testing the effects of dose and schedule. RmB7.2-Ig in combination with some chemotherapeutics enhances the activity and efficacy of reduced chemotherapeutic doses. However, the relative timing of chemotherapy and rmB7.2-Ig dosing can be important. Investigation of mechanisms of action based on histological studies suggests that inflammatory as well as T cell mechanisms comprise the response. Additional studies of mice deleted of B7.1, B7.2, and CTLA-4 suggest that the enhanced response induced by rmB7.2-Ig may not be mediated through CD28 ligation alone. The efficacy suggests potential for recombinant human B7.2-Ig as an adjuvant to chemotherapy in promoting immune-mediated mechanisms to augment the activity of chemotherapy.


Subject(s)
Antigens, CD/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Immunoglobulin Heavy Chains/therapeutic use , Immunotherapy , Membrane Glycoproteins/therapeutic use , Neoplasms, Experimental/therapy , Animals , Antigens, CD/immunology , Apoptosis/drug effects , B7-2 Antigen , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Humans , Immunoglobulin Heavy Chains/immunology , Membrane Glycoproteins/immunology , Membrane Glycoproteins/pharmacokinetics , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Neoplasms, Experimental/immunology , Neoplasms, Experimental/pathology , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/pharmacokinetics , Recombinant Fusion Proteins/therapeutic use
2.
Oral Oncol ; 36(4): 373-81, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10899677

ABSTRACT

Oral ulcerative mucositis is a common toxicity associated with drug and radiation therapy for cancer. It impacts on quality of life and economic outcomes, as well as morbidity and mortality. Mucositis is often associated with dose limitations for chemotherapy or is a cause for dose interruption for radiation. The complexity of mucositis as a biological process has only been recently appreciated. It has been suggested that the condition represents a sequential interaction of oral mucosal cells and tissues, pro-inflammatory cytokines and local factors such as saliva and the oral microbiota. The recognition that the pathophysiology of mucositis is a multifactorial process was partially suggested by the observation that interleukin-11 (IL-11), a pleotropic cytokine, favorably altered the course of chemotherapy-induced mucositis in an animal model. In the current study, we evaluated a series of biologic and morphologic outcomes to determine their roles and sequence in the development of experimental radiation-induced mucositis and to evaluate the effects of IL-11 in attenuating them. Our results suggest that IL-11 favorably modulates acute radiation-induced mucositis by attenuating pro-inflammatory cytokine expression. Data are also presented which help define the pathobiological sequence of mucositis.


Subject(s)
Interleukin-11/therapeutic use , Radiation Injuries, Experimental/prevention & control , Stomatitis/prevention & control , Animals , Apoptosis , Cricetinae , Disease Progression , Head and Neck Neoplasms/radiotherapy , Immunohistochemistry , Interleukin-1/therapeutic use , Keratins/metabolism , Male , Mast Cells , Mesocricetus , Mouth Mucosa , Oral Ulcer/etiology , Oral Ulcer/pathology , Oral Ulcer/prevention & control , Stomatitis/etiology , Stomatitis/pathology
3.
Exp Hematol ; 22(3): 295-301, 1994 Mar.
Article in English | MEDLINE | ID: mdl-8112427

ABSTRACT

Lethally irradiated mice were transplanted with syngeneic bone marrow cells infected with a recombinant retrovirus vector containing the human interleukin-11 (hIL-11) cDNA under the control of the human cytomegalovirus (CMV) immediate early promoter. The hIL-11 RNA transcript from the vector was detected in the spleen and bone marrow of the recipient mice, and hIL-11 protein accumulated in their serum. The hematological reconstitution of these mice was compared with recipient mice rescued with bone marrow infected with the parental retrovirus vector not containing the hIL-11 cDNA. The hIL-11-expressing mice had an accelerated recovery of circulating platelets and red and white blood cells. Three months after the transplantation, bone marrow was harvested from the mice and used to rescue other lethally irradiated recipients. The hIL-11 mRNA and protein were also detected in these secondary recipients, and the mice showed improved hematological reconstitution relative to a control group. No abnormal cell proliferation or other histopathology was observed in the hIL-11-expressing mice.


Subject(s)
Bone Marrow Transplantation/pathology , Bone Marrow/chemistry , Bone Marrow/pathology , Bone Marrow/radiation effects , Hematopoiesis/physiology , Interleukin-11/analysis , Interleukin-11/physiology , Animals , Cell Line , DNA, Viral/analysis , DNA, Viral/genetics , Dose-Response Relationship, Drug , Female , Genetic Vectors , Hematopoiesis/drug effects , Hematopoiesis/radiation effects , Interleukin-11/genetics , Mice , Mice, Inbred C3H , RNA, Messenger/analysis , RNA, Messenger/genetics , Retroviridae/genetics , Spleen/chemistry , Spleen/cytology , Tissue Donors , Transfection
4.
Arterioscler Thromb ; 14(1): 70-6, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8274480

ABSTRACT

Previous studies have demonstrated that short-term administration of recombinant human macrophage colony-stimulating factor (rhM-CSF) reduces plasma cholesterol in rabbits, nonhuman primates, and human subjects. This study extended the dose schedule of rhM-CSF to 8 weeks of continuous intravenous infusion (CIV) in the Watanabe heritable hyperlipidemic (WHHL) rabbit and expanded the scope to include an assessment of macrophage-derived foam cell development. Ten male WHHL rabbits were injected subcutaneously with 1% carrageenan to promote formation of a macrophage-rich foam cell granuloma. Rabbits were infused with either vehicle or rhM-CSF at 100 micrograms/kg per day (weeks 1 through 5) followed by 300 micrograms/kg per day (weeks 6 through 8). rhM-CSF (100 micrograms/kg per day) decreased total plasma cholesterol by 45% at 2 weeks compared with controls. The gradual return of plasma cholesterol toward control concentrations over the subsequent 3 weeks correlated with the appearance of circulating antibodies specific to rhM-CSF. Granuloma weights at harvest (8 weeks after infusion) were significantly lower (2.8 +/- 0.7 g, mean +/- SEM) in rhM-CSF-treated rabbits relative to controls (7.1 +/- 1.5 g, P < .05). Granulomas from rabbits treated with rhM-CSF contained lower concentrations of cholesterol (2.0 +/- 0.7 versus 6.1 +/- 1.5 micrograms/mg, P < .03) and cholesteryl ester (0.7 +/- 0.4 versus 3.9 +/- 1.2 micrograms/mg, P < .03) than controls. Histological evaluation revealed that granulomas from the rhM-CSF-treated rabbits were more fibrous and contained fewer foam cells than those from controls.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Carrageenan , Cholesterol/blood , Granuloma/pathology , Hyperlipidemias/drug therapy , Macrophage Colony-Stimulating Factor/pharmacology , Animals , Antibodies/blood , Cholesterol/metabolism , Granuloma/chemically induced , Humans , Hyperlipidemias/blood , Hyperlipidemias/pathology , Immunohistochemistry , Leukocyte Count , Macrophage Colony-Stimulating Factor/metabolism , Macrophage Colony-Stimulating Factor/therapeutic use , Macrophages/pathology , Male , Platelet Count , Rabbits , Recombinant Proteins/pharmacology , Recombinant Proteins/therapeutic use
5.
J Invest Surg ; 6(1): 33-52, 1993.
Article in English | MEDLINE | ID: mdl-8452823

ABSTRACT

Thermal balloon angioplasty has been proposed as a means of reducing acute and delayed reclosure of arteries after percutaneous transluminal balloon angioplasty. A radiofrequency (rf) balloon catheter was used to perform thermal balloon angioplasty on canine arteries in vivo. The histologic appearance of rf-treated sites was compared with that of control sites treated by conventional percutaneous transluminal angioplasty. Acutely, rf-treated sites showed a reduced medial cellularity with preservation of internal elastic lamina except at the transitional zone between thermal injury and normal artery, where localized internal elastic lamina disruption was found. Nonthermal sites showed generalized disruption of internal elastic lamina and normal medial cellularity. Both thermal and nonthermal sites displayed a return of intimal cover commencing at 1 to 2 weeks and completed by 4 weeks. Diffuse myointimal hyperplasia appeared by 2 weeks after injury at breaks in the internal elastic lamina along the nonthermal vessels but was localized to the transitional zone in thermal injury sites. In rf-treated vessels, repopulation of the acellular thermally modified media had commenced by 4 weeks, and by 8 weeks the media was diffusely repopulated by spindle-shaped cells resembling smooth muscle cells lying between and aligned with preserved connective tissue laminae. Overall, the distribution and extent of the proliferative response after rf thermal balloon angioplasty were less than those seen after nonthermal balloon angioplasty. Thermal sites, which underwent reintimalization before medial cells returned, were considerably less prone to the development of myointimal hyperplasia. These results suggest that this modality may have beneficial effects on arterial healing after angioplasty.


Subject(s)
Angioplasty, Balloon/methods , Arteries/physiology , Radio Waves , Wound Healing/physiology , Angiography , Animals , Arteries/pathology , Dogs , Hot Temperature , Hyperplasia , Microscopy, Electron, Scanning , Muscle, Smooth, Vascular/pathology
6.
Scanning Microsc ; 4(2): 341-9; discussion 349-50, 1990 Jun.
Article in English | MEDLINE | ID: mdl-2402609

ABSTRACT

Hydrogels are a class of synthetic material, composed of a polymer-water matrix and have been proposed as tissue substitutes and drug delivery vehicles. Polyethylene oxide (PEO) hydrogels were synthesized and used to produce coated wires and conduits for baboon blood compatibility studies. Blood-material interactions were studied both by Scanning Electron Microscopy (SEM) and 111In labeled platelet deposition. SEM processing modifications were first evaluated in order to reduce shrinkage and surface distortion incurred during sample preparation of these high water content materials. Pretreatment with 1% tannic acid reduced bulk shrinkage associated with critical point drying by 10-20%. This effect is small, nevertheless, it prevented major sample disruption. Coated guidewires were exposed to baboon blood for one hour in the inferior vena cava and conduits were placed for either 30 or 60 minutes in an ex vivo femoral arteriovenous shunt. Reference materials included Gore-tex, polyethylene and silica-free polydimethyl siloxane (PDMS). In the guidewire studies, 111In labeled platelet levels were highest on Gore-tex (6568.97 platelets/1000 microns 2) and large thrombotic deposits were well visualized by SEM. Formulations containing PEO had low levels of platelet deposition and little evidence of platelet activation was noted by SEM. Shunt studies demonstrated that materials of high PEO content and molecular weight had the lowest levels of platelet deposition. After 60 minutes of blood flow, mean platelet deposition on PDMS and Gore-tex was 50 and 1000 fold higher than on a network composed of 65% PEO 20,000 (p less than 0.05). SEM confirmed these findings.


Subject(s)
Biocompatible Materials , Blood Platelets/ultrastructure , Polyethylene Glycols , Analysis of Variance , Animals , Hydrogel, Polyethylene Glycol Dimethacrylate , Male , Materials Testing , Microscopy, Electron, Scanning/methods , Papio
7.
Behav Neurosci ; 101(4): 587-90, 1987 Aug.
Article in English | MEDLINE | ID: mdl-3651236

ABSTRACT

A delayed nonmatching-to-sample task with trial-unique stimuli (DNMS), similar to that used to test object recognition memory in primates, was adapted for use with rats. For each trial of the DNMS task, two stimuli were randomly selected from a pool of 250 small "junk" objects; one member of the pair was designated as the sample. On the first part of a trial, the rat traversed an elevated runway and displaced the sample for food reward. After a 10-s delay, the rat again traversed the runway to choose between the previously presented sample and the second member of the pair. Reward on the choice trial followed selection of the new object. Scores on the first day of DNMS were significantly above chance, and animals could consistently perform at approximately 75% accuracy. Extending the delay to 30 or 120 s lowered choice accuracy, but performance was still above chance. The DNMS taks for rats, unlike most other memory tests for rodents, does not require memory for spatial location. The similarity to tests used with primates should allow for more direct comparison of results of memory research across species.


Subject(s)
Attention , Form Perception , Memory, Short-Term , Memory , Mental Recall , Pattern Recognition, Visual , Animals , Rats , Rats, Inbred Strains
SELECTION OF CITATIONS
SEARCH DETAIL
...